System of medical indicators having multisensory, multipurpose and multifunctional features

ABSTRACT

A system including a plurality of indicator tags, each of which includes a body having a first end, a second end, a first surface extending from the first end to the second end, a second surface extending from the first end to the second end, and an aperture sized and shaped to receive a corresponding intravenous tube extending from the first end to the second end intermediate the first surface and the second surface, at least one of the first and second surfaces including a haptic signature, wherein the plurality of indicator tags includes at least one tag of a first type and at least one tag of a second type, wherein the haptic signature of the at least one tag of the first type corresponds to a first medication, wherein the haptic signature of the at least one tag of the second type corresponds to a second medication.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of commonly-owned, co-pendingU.S. patent application Ser. No. 16/529,441, titled “SYSTEM OF MEDICALINDICATORS HAVING MULTISENSORY, MULTIPURPOSE AND MULTIFUNCTIONALFEATURES,” having a filing date of Aug. 1, 2019, which is a Section111(a) application relating to and claiming the benefit ofcommonly-owned, co-pending U.S. Provisional Patent Application No.62/724,424, titled “ADMINISTRATION OF MEDICAMENTS THROUGH INTRAVENOUSTUBING USING MULTISENSORY FEATURES AND OTHER INDICATORS—A SYSTEM TOREDUCE MEDICATION ERRORS AND INFORM PATIENTS,” having a filing date ofAug. 29, 2018, the contents of both of which are incorporated byreference herein in their entirety.

FIELD OF THE INVENTION

The present invention relates to indicators for labelling andidentifying intravenous (“IV”) tubing, and the contents thereof, usingsensory stimuli, such as visual and haptic (i.e., tactile; pertaining tothe sensation of touch) signatures and other identifiers.

BACKGROUND

Literature suggests that medical errors constitute the third highestcause of death in the United States. Among medical errors, humanmedication errors rank first. By reducing human error in theadministration of intravenous medication/fluid, more than 7,000 livesmight be saved each year, and a similar volume of medication-relatedpatient complications may be avoided.

What is needed is a system that reduces medical errors by (1) providinga mechanism(s) to limit medical errors during a medical crisis; (2)identifying a “safe-line” for medical personnel to use in a medicalemergency; (3) creating patient, patient family or advocate awareness oftherapy; (4) allowing quick, cognitive recognition of medical care atmedical shift change; (5) enumerating the number of differentmedications/fluids in use or that have been administered; and (6)avoiding the inadvertent administration of therapy in a non-intravenousline (e.g., a spinal line or an arterial line rather than a venousline).

Tubing used for infusion is generic, clear and indistinguishable fromother lines in use regardless of the tubing's contents. The tubing ispart of an intravenous (IV) line. This line is also known as an infusionset, IV set, infusion line, or simply “the line”. IV fluids areadministered through a thin, flexible transparent plastic tube. The IVtube line connects to the bag of IV solution. This line is used toinfuse, continuously or intermittently, fluids or medication. Itincludes the following: (1) a spike and drip chamber which attaches tothe bag of fluid; (2) backcheck valve which prevents fluid or medicationfrom travelling up the line; (3) access ports, which are used to infusesecondary medications and give push medications; and (4) a roller clamp,which is used to regulate the speed of, or to stop or start, a gravityinfusion. The number of lines needed for infusion therapy depends on themedical condition of the patient and how acutely ill the patient is atthe time.

SUMMARY OF THE INVENTION

The exemplary embodiments present a novel method to avoid and reduce theprobability of medication errors in patients receiving IV therapy.

The exemplary embodiments provide a mechanism for the rapid and repeatedidentification of the correct IV line to use in an emergency situation.In a medical crisis, care is often chaotic and multiple lines may beneeded or are already in use. When an emergency medication is needed,safe, fast, and confident delivery of the medication through thecorrect, existing IV line(s) is essential. The correct IV line mustcarry a fluid which is compatible with all emergency medications and thecorrect IV line must be frequently recognized for repeated use, ifneeded.

The exemplary embodiments provide a “safe-line” or “tag” on anappropriate line that facilitates rapid identification of a “safe” lineto use in the emergency. Such a critical situation routinely arisesduring aeromedical and ground medical transport, but can likewise happenin a pre-hospital (e.g., ambulance or medical airlift) or hospitalenvironment.

The exemplary embodiments further provide the application of a specificlabel on the line to denote the medication in use. This provides aunique ability for both the caregivers, the patient (self-care), as wellas patient's advocate or family in attendance, to become informed of themedication in use. This also provides critical information regarding theinitiation, duration and cessation of the medication for the patient. Itconfirms patient and family expectations regarding information they havebeen told about current and future treatment. It provides an additionalcheck on the therapy as well as to avoid errors by caregivers.

The exemplary embodiments provide immediate cognitive awareness at shiftchange in a pre-hospital or hospital environment. This also applies withthe entry of medical personnel into the patient's room whether they arefamiliar with the patient, or not. This information is important sincechanges in patient care may have occurred in the interim since thepatient was last seen or examined either by a nurse or physician (e.g.,initiation of anticoagulation in a patient expected to go for surgery).Furthermore, there may have been a lack of communication regarding thesechanges (or information missed because of the complexity of, ordeficiency in, the medical record). This immediate cognitive awarenessis particularly important in an academic environment where traineecaregivers are in abundance and the risks of medical errors are higher.

The exemplary embodiments provide an identification system that embodiesa mechanism for the enumeration of the number of medication(s) in use(e.g., multiple medications of the same class). In so doing thisadditionally allows for the awareness of either the deterioration orimprovement in the patient's condition for both caregiver, patient andfamily. This would be the case such as when the number of pressor (bloodpressure medication) tags are increased or decreased respectively.Finally, the numerical ability of the blood transfusion tag allows forthe tabulation of the number of units of the blood product infused aswell as confirmation of the patient's blood type.

The exemplary embodiments assist in the prevention of the administrationof certain medications into an inappropriate line that may result incatastrophic morbidity or death (e.g., vincristine chemotherapy givenintrathecally). Just as it is important for the content of an IV line tobe easily identified by caregivers, so it is of critical importance foran incorrect line to be readily recognizable to avoid an administrationerror.

In an embodiment, an indicator includes a body having a first end, asecond end opposite the first end, a first surface and a second surfaceopposite the first surface, each of which extends from the first end tothe second end, and an aperture extending from the first end to thesecond end, the aperture being sized and shaped to receive a tube, andat least one of the first and second surfaces including a hapticsignature formed thereon.

In an embodiment, the haptic signature is embossed on the at least oneof the first and second surfaces. In an embodiment, the haptic signatureincludes a height in a range of 0.02 inch and 0.08 inch.

In an embodiment, the haptic signature is debossed on the at least oneof the first and second surfaces. In an embodiment, the haptic signatureincludes depth in a range of 0.02 inch to 0.08 inch.

In an embodiment, the haptic signature includes a plurality of indiciaelements spaced apart from one another. In an embodiment, a spacingbetween an adjacent pair of the plurality of indicia elements is in arange of 0.02 inch to 0.08 inch. In an embodiment, the plurality ofindicia elements includes a series of elements having similar shapes,each of the series of elements includes a height that varies from theheight of another of the series of elements. In an embodiment, each ofthe heights of the series of elements of the plurality of indiciaelements is in a range of 0.005 inch to 0.08 inch.

In an embodiment, the haptic signature includes a textured portionhaving a grainy texture. In an embodiment, the textured portion includesa plurality of grains having sizes in a range of about 0.005 inch toabout 0.010 inch.

In an embodiment, the haptic signature includes a first end, a secondend opposite the first end of the haptic signature, and a width thatvaries along a length extending from the first and second ends of thehaptic signature, wherein the width varies within a range of 0.05 inchto 0.5 inch.

In an embodiment, the haptic signature includes an embossed portion anda debossed portion, wherein the embossed portion includes a height in arange of 0.02 inch and 0.08 inch, and debossed portion includes a depthin a range of 0.02 inch to 0.08 inch.

In an embodiment, the haptic signature includes an embossed portion anda debossed portion that is debossed within the embossed portion, whereinthe embossed portion includes a height in a range of 0.02 inch and 0.08inch, and the debossed portion includes a depth in a range of 0.02 inchto 0.08 inch.

In an embodiment, the body includes a first member and a second memberconnected movably to the first member, wherein each of the first andsecond members includes an interior surface and a channel formed withinthe interior surface and extending from a first end thereof to a secondend thereof, wherein the first and second members are movable between anopen position and closed position, and wherein the channels of each ofthe first and second members form the aperture when the first and secondmembers are in their closed position.

In an embodiment, the first member of the body includes at least one tabextending from the interior surface thereof, and the second member ofthe body includes at least one groove formed within the interior surfacethereof, and wherein the at least one tab is sized and shaped to engageremovably the at least one groove. In an embodiment, the body includesat least one hinge connected to the first and second members.

In an embodiment, the body includes a plurality of removable tabs.

In an embodiment, the tube is an intravenous tube and the hapticsignature corresponds to a medication delivered by the intravenous tube.

In an embodiment, a combination includes at least one intravenous tubeand a plurality of indicators, each indicator comprising a body having afirst end, a second end opposite the first end, a first surface and asecond surface opposite the first surface, each of which extends fromthe first end to the second end, and an aperture extending from thefirst end to the second end, the aperture being sized and shaped toreceive the at least one intravenous tube, and at least one of the firstand second surfaces including a haptic signature formed thereon, thehaptic signature corresponding to a medication delivered by the at leastone intravenous tube.

In an embodiment, the haptic signature of a first one of the pluralityof indicators is different from the haptic signature of a second one ofthe plurality of indicators.

In an embodiment, the haptic signature of each of the plurality ofindicators is different from the haptic signature of others of theplurality of indicators.

In an embodiment, the at least one intravenous tube includes a pluralityof intravenous tubes, and the haptic signature of the first one of theplurality of indicators corresponds to a medication delivered by a firstone of the plurality of intravenous tubes, and the haptic signature ofthe second of the plurality of indicators corresponds to anothermedication delivered by a second one of the plurality of intravenoustubes.

In an embodiment, the haptic signature of each of at least two of theplurality of indicators are identical to one another. In an embodiment,the haptic signature of each of at least three of the plurality ofindicators are identical to one another.

In an embodiment, a system includes a plurality of indicator tags, eachof which includes a body having a first end, a second end opposite thefirst end, a first surface extending from the first end to the secondend, a second surface opposite the first surface and extending from thefirst end to the second end, and an aperture extending from the firstend to the second end and intermediate the first surface and the secondsurface, the aperture being sized and shaped to receive a correspondingintravenous tube, and at least one of the first and second surfacesincluding a haptic signature formed thereon, wherein the plurality ofindicator tags includes at least one tag of a first type and at leastone tag of a second type, wherein the haptic signature of the at leastone tag of the first type corresponds to a first medication, and whereinthe haptic signature of the at least one tag of the second typecorresponds to a second medication and is different from the hapticsignature of the at least one tag of the first type.

In an embodiment, each of the plurality of indicator tags furthercomprises a visual indicator, wherein the visual indicator of the atleast one indicator tag of the first type is different from the visualindicator of the at least one indicator tag of the second type. In anembodiment, the visual indicator includes a color, and the at least oneindicator tag of the first type has a first color and the at least oneindicator tag of the second type has a second color that is differentfrom the first color. In an embodiment, the visual indicator includes atext label, and the at least one indicator tag of the first type has afirst text label corresponding to the first medication, and wherein theat least one indicator tag of the second type has a second text labelcorresponding to the second medication.

In an embodiment, the system includes three indicator tags of the firsttype, and each of the three indicator tags of the first type isconfigured to be secured at a different location along its correspondingintravenous tube. In an embodiment, a first one of the indicator tags ofthe first type is configured to be secured to the correspondingintravenous tube near a connector to a bag of fluid, a second one of theindicator tags of the first type is configured to be secured to thecorresponding intravenous tube near a peristaltic pump insert or a flowrate adjusting roller clamp, and a third one of the indicator tags ofthe first type is configured to be secured to the correspondingintravenous tube near an access port at a distal end of thecorresponding intravenous tube.

In an embodiment, the haptic signature of the at least one indicator tagof the first type is an embossed haptic signature that is embossed onthe at least one of the first and second surfaces of the at least oneindicator tag of the first type. In an embodiment, the embossed hapticsignature includes a height in a range of 0.01 inch and 0.08 inch.

In an embodiment, the haptic signature of the at least one indicator tagof the first type is a debossed haptic signature that is debossed on theat least one of the first and second surfaces of the at least oneindicator tag of the first type. In an embodiment, the debossed hapticsignature includes depth in a range of 0.02 inch to 0.08 inch.

In an embodiment, the haptic signature of the at least one indicator tagof the first type includes a plurality of indicia elements spaced apartfrom one another. In an embodiment, a spacing between an adjacent pairof the plurality of indicia elements is in a range of 0.02 inch to 0.08inch. In an embodiment, the plurality of indicia elements includes aseries of elements having similar shapes, each of the series of elementsincludes a height that varies from the height of another of the seriesof elements. In an embodiment, each of the heights of the series ofelements of the plurality of indicia elements is in a range of 0.005inch to 0.08 inch.

In an embodiment, the haptic signature of the at least one indicator tagof the first type includes a textured portion. In an embodiment, thetextured portion includes a plurality of hemispherical dots havingheights in a range of from 0.17 mm to 1 mm and a center-to-centerspacing between adjacent dots in a range of from 1 mm to 1.5 mm. In anembodiment, the textured portion includes a plurality of hemisphericaldots having heights in a range of from 1 mm to 1.2 mm and acenter-to-center spacing between adjacent dots in a range of that isfrom 1.5 mm to 2.5 mm.

In an embodiment, the haptic signature of the at least one indicator tagof the first type includes an embossed portion and the haptic signatureof the at least one indicator tag of the second type includes a texturedportion.

In an embodiment, the haptic signature of the at least one indicator tagof the first type includes an embossed portion and the haptic signatureof the at least one indicator tag of the second type includes a debossedportion.

In an embodiment, the haptic signature of the at least one indicator tagof the first type includes a debossed portion and the haptic signatureof the at least one indicator tag of the second type includes a texturedportion.

In an embodiment, a system includes at least two intravenous tubes, eachof which has a proximal end, a distal end opposite the proximal end, anda middle portion intermediate the proximal and distal ends, wherein afirst one of the intravenous tubes carries a first medicament, andwherein a second one of the intravenous tubes carries a secondmedicament; a plurality of indicator tags, each of which is configuredto be attached to one of the at least two intravenous tubes, and whereineach of the indicator tags includes a haptic signature formed on atleast one of the first and second surfaces and providing multi-sensoryinput to a user, wherein the plurality of indicator tags includes atleast a first type of indicator tag and a second type of indicator tag,wherein the haptic signature and the visual indicator of the first typeof indicator tag provide a first type of multi-sensory input indicativeof the first medicament, wherein a first one of the first type ofindicator tag is attached to the first one of the intravenous tubes atthe proximal end of the first one of the intravenous tubes, wherein asecond one of the first type of indicator tag is attached to the firstone of the intravenous tubes at the middle portion of the first one ofthe intravenous tubes, wherein a third one of the first type ofindicator tag is attached to the first one of the intravenous tubes atthe distal end of the first one of the intravenous tubes, wherein thehaptic signature and the visual indicator of the second type ofindicator tag provide a second type of multi-sensory input differentfrom the first type of multi-sensory input and indicative of the secondmedicament, wherein a first one of the second type of indicator tag isattached to the second one of the intravenous tubes at the proximal endof the second one of the intravenous tubes, wherein a second one of thesecond type of indicator tag is attached to the second one of theintravenous tubes at the middle portion of the second one of theintravenous tubes, wherein a third one of the second type of indicatortag is attached to the second one of the intravenous tubes at the distalend of the second one of the intravenous tubes.

In an embodiment, the visual indicator of each of the plurality ofindicator tags includes at least one of a color, a text label, an image,or combinations thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further explained with reference to theattached drawings, wherein like structures are referred to by likenumerals throughout the several views. The drawings shown are notnecessarily to scale, with emphasis instead generally being placed uponillustrating the principles of the present invention.

FIG. 1 is a top perspective view of an embodiment of an intravenoustubing indicator;

FIG. 2 is top plan view thereof, the bottom plan view being a mirrorimage thereto;

FIG. 3 is a front elevation view thereof, the rear elevational viewbeing a mirror image thereto;

FIG. 4 is a left side elevational view thereof, the right sideelevational view being a mirror image thereof;

FIG. 5 is a top perspective view thereof, with the indicator beingattached to tubing;

FIG. 6 is a top perspective view thereof, with the indicator including ahaptic signature on a surface thereof;

FIG. 7 is a top perspective view of another embodiment of an intravenoustubing indicator in a closed position;

FIG. 8 is a top plan view thereof;

FIG. 9 is a bottom plan view thereof;

FIG. 10 is a front elevational view thereof;

FIG. 11 is a rear elevational view thereof;

FIG. 12 is a left side elevational view thereof;

FIG. 13 is a right side elevational view thereof;

FIG. 14 is a top perspective view thereof, with the indicator beingattached to tubing;

FIG. 15 is a top perspective view thereof, with the indicator includinga haptic signature on a surface thereof;

FIG. 16 is a top perspective view of the intravenous tubing indicator ofFIG. 7 but in an open position;

FIG. 17 is a top plan view thereof;

FIG. 18 is a bottom plan view thereof;

FIG. 19 is a front elevational view thereof;

FIG. 20 is a rear elevational view thereof;

FIG. 21 is a left side elevational view thereof;

FIG. 22 is a right side elevational view thereof;

FIG. 23 is a bottom plan view of another embodiment of the intravenoustubing indicator, with interior fastening elements;

FIG. 24A is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for an antihypertensive;

FIG. 24B is a rear perspective view of the intravenous tubing indicatorof FIG. 24A;

FIG. 25A is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for an antibiotic;

FIG. 25B is a rear perspective view of the intravenous tubing indicatorof FIG. 25A;

FIG. 26A is a front perspective view of another embodiment of a tubingindicator including an exemplary haptic signature/visual for an arterialline;

FIG. 26B is a rear perspective view of the tubing indicator of FIG. 26A;

FIG. 27A is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for a venous line;

FIG. 27B is a rear perspective view of the intravenous tubing indicatorof FIG. 27A;

FIG. 28A is a front perspective view of another embodiment of a tubingindicator including an exemplary haptic signature/visual for spinaladministration;

FIG. 28B is a rear perspective view of the tubing indicator of FIG. 28A;

FIG. 29 is a front perspective view of another embodiment of a tubingindicator including an exemplary haptic signature/visual for a portcover (Do Not Use);

FIG. 30 is a front perspective view of another embodiment of a tubingindicator including an exemplary haptic signature/visual forincompatible medications (i.e., to be administered alone);

FIG. 31 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for an antiarrhythmic;

FIG. 32 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for an anticoagulant;

FIG. 33 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for a narcotic;

FIG. 34 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for blood transfusion;

FIG. 35 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for a pressor;

FIG. 36 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for a paralytic;

FIG. 37 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for insulin;

FIG. 38 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for a sedative (i.e., sedation);

FIG. 39 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for chemotherapy;

FIG. 40 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for total parenteral nutrition (TPN);

FIG. 41 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for pediatric dosing;

FIG. 42 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for potassium;

FIG. 43 is a front perspective view of another embodiment of anintravenous tubing indicator including an exemplary hapticsignature/visual for obstetric administration; and

FIG. 44 is a photograph of a prototype example of an exemplaryintravenous tubing indicator.

FIG. 45 is a perspective view of another embodiment of intravenoustubing indicators.

FIG. 46 is a perspective view of another embodiment of intravenoustubing indicators.

DETAILED DESCRIPTION OF THE DRAWINGS

Multiple intravenous (IV) tubing indicators (sometimes referred toherein as “tags”) are disclosed. Such indicators are affixed tointravenous tubing in a hospital or other medical environment. Thesefunction to provide to caregivers and patients more efficient, reliableand accurate identification of medications or other substances beingconveyed to the patient via the IV tubing.

In some embodiments, the intravenous tubing indicators are haptic (i.e.,tactile; pertaining to the sensation of touch). This assists withrecognition of the indicator and, thereby, the medication, by feel, aswell as in conditions of low light. In some embodiments, the indicatorsare fabricated to convey multi-sensory communications to a user (e.g., aphysician, nurse, or other medical clinician treating a patient) toprovide further recognition regarding the medication or other substancescontained in the intravenous tubing. In some embodiments, themulti-sensory communication may include symbols, print/text, color,shape, luminosity (e.g., generated by a luminescent) and/ortouch/tactile stimuli. Specific combinations of multi-sensorycommunications correspond and alert the caregivers to different classesor types of medication or fluids. This reminds or warns the user of thecontents of the intravenous tubing, in order to take appropriate actionin connection therewith, should this be necessary (e.g., the insulin taghas a grainy feel/texture resembling sugar). Use of the intravenoustubing indicators thereby minimizes or prevents medication-relatederrors that can be catastrophic, and even fatal, to the patient.

In some embodiments, the indicators include a system of IV-line tagswith haptic signatures for the use of differentiating medications orfluids through various sensory modalities including visual symbols,luminosity, print/text, color, textures, luminosity and touch. Eachdistinct haptic signature is located on its own tag that is configuredto be placed on multiple locations of the IV tubing to prevent IV-linemix-ups and errors.

In some embodiments, the indicators are plastic tags that are secured tothe IV line. In some embodiments, the plastic tags are injection molded.In some embodiments, the tags are clip-on tags (that cannot be removed).In some embodiments, one or more separate clips is/are used to attachthe tags to the IV line. In some embodiments, the clips are removable.In some embodiments, a face of the tag includes a centralized hapticsignature that fits the thumb of a user. In some embodiments, an outerring surrounding the haptic signature includes a label at the top andpull/twist off indicators on each side that numerically indicate thenumber of similar lines (or class of drug) in use. In some embodiments,a back of the tag includes two snap-on features that allow for easyconnection to IV tubing. In some embodiments, the haptic tags are sizedso as to fit the fingers of most males and most females. In someembodiments, the haptic tags are sized so as to fit different fingersizes within a range spanning, at the smallest end, the 5th percentileof female fingers and, at the largest end, the 95th percentile of malefingers. In one embodiment, the haptic tags are approximately 2 inchestall by 1.5 inches wide, which is a size that accounts for the 5thpercentile female fingers and the 95th percentile male fingers.

The indicators (e.g. tags) allow medical personnel to easily locate andidentify IV-lines through their corresponding haptic signatures andvisual cues. Tags closer to the patient allow for quick and easyidentification. A user may identify a specific tag through a range ofsensory modalities including color, label, luminosity, symbol, ortexture. The haptic signature is positioned so that a user's thumb caneasily “read” with natural thumb flexion while still being able to seethe label and color associated with the tag. In some embodiments, ahaptic signature that is sized and shaped to fit a user's thumb providesa semantic cue to induce the user to place the user's thumb over thehaptic signature.

In various embodiments, an individual tag includes a color, label, and aspecific haptic signature to identify the drug with which it isassociated. Haptic signatures include textures, icons, and metaphorsthat are meaningful and familiar to clinical professionals (e.g. grainyfeel/texture resembling sugar for insulin line; prickly feel/texture fornarcotic lines; wavy feel/texture for anticoagulants) To differentiateshapes and prevent confusion between tags, haptic signatures may includevarying heights, spacing, textures, degrees of roughness, and/or sizesin various embodiments.

In some embodiments, each tag (except for insulin) includes sequentiallynumbered pull/twist-off tabs to indicate the number of IV bags a patienthas used in a day. The insulin tag should not include any pull/twist-offtabs to prevent confusion and overdosing (see FIG. 37). Bloodtransfusion lines have different tabs (see FIG. 34 that allow medicalpersonnel to indicate the blood type of the patient as well as how manytransfusions they have received in a day (e.g., by removing one tab atthe time of each transfusion, by removing a quantity of tabscorresponding to the number of transfusions that have been received,etc.).

FIGS. 1-6 illustrate a first exemplary embodiment of an intravenoustubing indicator 100 according to the present disclosure. The indicator100 includes a body 102 that is monolithically formed, and has twoopposed ends 104, 106. Opposed sides 108, 110 extend between ends 104,106. Opposed top and bottom surfaces 112, 114 extend between ends 104,106 and are bordered by sides 108, 110. A central, longitudinal apertureextends through the body 102 from the end 104 to the end 106, such thatthe end 104 defines an aperture 116 therein, and the end 106 defines anaperture 118 therein. Apertures 116, 118 are dimensioned so as toreceive a length of intravenous tubing T therethrough. Moreparticularly, the intravenous tubing T is inserted through aperture 116,extended along the interior of the indicator body 102, and exitstherefrom through aperture 118, as shown in FIG. 5.

At least one of the top or bottom surfaces 112, 114 on the indicatorbody 102 includes a haptic signature 120. The haptic signature 120 mayinclude images, designs, numbers, letters, punctuation marks, patterns,other indicia, or any combination thereof (collectively “indicia”). Thehaptic signature 120 is formulated to convey to a user (e.g., aphysician, nurse or other medical personnel treating a patient) thenature of the medication or other substance that is contained within theintravenous tubing T and being delivered to the patient thereby. Thehaptic signature 120 is formed on the surface(s) 112, 114 of theindicator body 102 by any means known in the art, such as, for example,embossing, 3D printing, engraving, or as part of the injection-moldingprocess.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that is embossed on (i.e.,raised from) the corresponding one of the surfaces 112, 114 of theindicator body 102. In some embodiments, such a haptic signature 120 isembossed to a height that is selected to enable a user to identifyindicia in the haptic signature 120, and thereby to identify themedicament or other substance that is contained within the tubing T towhich the indicator 100 is attached. In some embodiments, the embossingheight is in a range of between 0.02 inch and 0.08 inch. In someembodiments, the embossing height is in a range of between 0.02 inch and0.04 inch. In some embodiments, the embossing height is in a range ofbetween 0.04 inch and 0.06 inch. In some embodiments, the embossingheight is in a range of between 0.06 inch and 0.08 inch. In someembodiments, the embossing height is in a range of between 0.02 inch and0.06 inch. In some embodiments, the embossing height is in a range ofbetween 0.04 inch and 0.08 inch. In some embodiments, the embossingheight is in a range of between 0.01 inch and 0.07 inch. In someembodiments, the embossing height is in a range of between 0.01 inch and0.03 inch. In some embodiments, the embossing height is in a range ofbetween 0.01 inch and 0.04 inch. In some embodiments, the embossingheight is in a range of between 0.01 inch and 0.05 inch. In someembodiments, the embossing height is in a range of between 0.01 inch and0.06 inch. In some embodiments, the embossing height is in a range ofbetween 0.05 inch and 0.07 inch. In some embodiments, the embossingheight is in a range of between 0.01 inch and 0.08 inch. In someembodiments, the embossing height is in a range of between 0.03 inch and0.07 inch. In some embodiments, the embossing height is about 0.01 inch.In some embodiments, the embossing height is about 0.015 inch. In someembodiments, the embossing height is about 0.02 inch. In someembodiments, the embossing height is about 0.03 inch. In someembodiments, the embossing height is about 0.04 inch. In someembodiments, the embossing height is about 0.05 inch. In someembodiments, the embossing height is about 0.06 inch. In someembodiments, the embossing height is about 0.07 inch. In someembodiments, the embossing height is about 0.08 inch. In someembodiments, the embossing height is in a range of between 0.5 and 0.55mm. In some embodiments, the embossing height is about 0.5 mm. In someembodiments, the embossing height is 0.5 mm. In some embodiments, theembossing height is 0.51 mm. In some embodiments, the embossing heightis in a range of between 0.9 mm and 1.1 mm. In some embodiments, theembossing height is about 1 mm. In some embodiments, the embossingheight is 1 mm. In some embodiments, the embossing height is in a rangeof between 1.4 and 1.6 mm. In some embodiments, the embossing height isabout 1.5 mm. In some embodiments, the embossing height is 1.5 mm. Insome embodiments, the embossing height is in a range of between 1.15 mmand 1.35 mm. In some embodiments, the embossing height is about 1.25 mm.In some embodiments, the embossing height is 1.25 mm. In someembodiments, the embossing height is in a range of between 0.3 mm and0.4 mm. In some embodiments, the embossing height is in a range ofbetween 0.3 mm and 0.36 mm. In some embodiments, the embossing height isabout 0.33 mm. In some embodiments, the embossing height is 0.33 mm. Insome embodiments, the embossing height is in a range of between 1.4 mmand 1.5 mm. In some embodiments, the embossing height is in a range ofbetween 1.4 mm and 1.44 mm. In some embodiments, the embossing height isabout 1.42 mm. In some embodiments, the embossing height is 1.42 mm.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that is debossed on (i.e.,depressed from) the corresponding one of the surfaces 112, 114 of theindicator body 102. In some embodiments, such a haptic signature 120 isdebossed to a depth that is selected so as to enable a user to identifyindicia in the haptic signature 120, and thereby to identify themedicament or other substance that is contained within the tubing T towhich the indicator 100 is attached. In some embodiments, the debossingdepth is in a range of between 0.02 inch and 0.08 inch. In someembodiments, the debossing depth is in a range of between 0.02 inch and0.04 inch. In some embodiments, the debossing depth is in a range ofbetween 0.04 inch and 0.06 inch. In some embodiments, the debossingdepth is in a range of between 0.06 inch and 0.08 inch. In someembodiments, the debossing depth is in a range of between 0.02 inch and0.06 inch. In some embodiments, the debossing depth is in a range ofbetween 0.04 inch and 0.08 inch. In some embodiments, the debossingdepth is in a range of between 0.4 mm and 0.6 mm. In some embodiments,the debossing depth is in a range of between 0.45 mm and 0.55 mm. Insome embodiments, the debossing depth is about 0.5 mm. In someembodiments, the debossing depth is 0.5 mm. In some embodiments, thedebossing depth is a range of between 0.8 mm and 1.2 mm. In someembodiments, the debossing depth is in a range of between 0.9 mm and 1.1mm. In some embodiments, the debossing depth is about 1 mm. In someembodiments, the debossing depth is 1 mm.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that includes a grainytexture formed on (i.e., raised from) the corresponding one of thesurfaces 112, 114 of the indicator body 102. In some embodiments, such ahaptic signature 120 includes a grainy texture that is selected so as toenable a user to identify indicia in the haptic signature 120, andthereby to identify the medicament or other substance that is containedwithin the tubing T to which the indicator 100 is attached. In someembodiments, the grainy texture includes individual grains of varyingsizes. In some embodiments, the grainy texture has a texture comparableto that of 100 grit sandpaper. In some embodiments, the grainy textureincludes grains having sizes that are in a range of between 0.005 inchand 0.010 inch. In some embodiments, the grainy texture includes grainshaving sizes that are in a range of between 0.005 inch and 0.006 inch.In some embodiments, the grainy texture includes grains having sizesthat are in a range of between 0.006 inch and 0.007 inch. In someembodiments, the grainy texture includes grains having sizes that are ina range of between 0.007 inch and 0.008 inch. In some embodiments, thegrainy texture includes grains having sizes that are in a range ofbetween 0.008 inch and 0.009 inch. In some embodiments, the grainytexture includes grains having sizes that are in a range of between0.009 inch and 0.010 inch. In some embodiments, the grainy textureincludes grains having sizes that are in a range of between 0.005 inchand 0.007 inch. In some embodiments, the grainy texture includes grainshaving sizes that are in a range of between 0.006 inch and 0.008 inch.In some embodiments, the grainy texture includes grains having sizesthat are in a range of between 0.007 inch and 0.009 inch. In someembodiments, the grainy texture includes grains having sizes that are ina range of between 0.008 inch and 0.010 inch. In some embodiments, thegrainy texture includes grains having sizes that are in a range ofbetween 0.005 inch and 0.008 inch. In some embodiments, the grainytexture includes grains having sizes that are in a range of between0.006 inch and 0.009 inch. In some embodiments, the grainy textureincludes grains having sizes that are in a range of between 0.007 inchand 0.010 inch. In some embodiments, the grainy texture includes grainshaving sizes that are in a range of between 0.005 inch and 0.009 inch.In some embodiments, the grainy texture includes grains having sizesthat are in a range of between 0.006 inch and 0.010 inch.

In some embodiments, the grainy texture includes a plurality ofgenerally hemispherical “dots” that are embossed on (i.e., raised from)a corresponding one of the surfaces 112, 114 of the indicator body 102.In some embodiments, each such dot has a diameter and a height from thecorresponding one of the surfaces 112, 114 that is half of the diameter.In some embodiments, such a plurality of embossed dots forms a matrixsuch that each such dot produces a pronounced point load at acorresponding location on the pad of a fingertip that is contacting thematrix of dots, thereby enhancing tactile sensation. In someembodiments, the diameter of each dot is from 0.34 mm to 3 mm, or from 1mm to 3 mm, or from 1.66 mm to 3 mm, or from 2.33 mm to 3 mm, or from0.34 mm to 2.33 mm, or from 1 mm to 2.33 mm, or from 1.66 mm to 2.33 mm,or from 0.34 mm to 1.66 mm, or from 0.34 mm to 1 mm, or from 1 mm to1.66 mm. In some embodiments, a matrix including dots of heights in arange of from 0.17 mm to 1 mm (i.e., having diameters in a range of from0.34 mm to 2 mm) has a center-to-center spacing between adjacent dotsthat is from 1 mm to 1.5 mm, or from 1 mm to 1.25 mm, or from 1.25 mm to1.5 mm. In some embodiments, a matrix including dots of heights in arange of from 1 mm to 1.2 mm (i.e., having diameters in a range of from2 mm to 3 mm) has a center-to-center spacing between adjacent dots thatis from 1.5 mm to 2.5 mm, or from 1.5 mm to 2 mm, or from 2 mm to 2.5mm.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that includes a plurality ofsimilar individual indicia elements (e.g., lines, curves, letters,symbols, etc.) that are spaced apart from one another along thecorresponding one of the surfaces 112, 114 of the indicator body 102. Insome embodiments, each such indicia element is embossed from thecorresponding one of the surfaces 112, 114 to a height such as one ofthe embossing heights discussed above. In some embodiments, each suchindicia element is debossed from the corresponding one of the surfaces112, 114 to a depth such as one of the debossing depths discussed above.In some embodiments, such a haptic signature 120 includes indiciaelements that are spaced apart from one another by a spacing distancethat is selected so as to enable a user to identify the indicia elementsin the haptic signature 120 as similar indicia elements that are spacedapart from one another, and thereby to identify the medicament or othersubstance that is contained within the tubing T to which the indicator100 is attached. In some embodiments, the spacing distance is in a rangeof between 0.02 inch and 0.08 inch. In some embodiments, the spacingdistance is in a range of between 0.02 inch and 0.04 inch. In someembodiments, the spacing distance is in a range of between 0.04 inch and0.06 inch. In some embodiments, the spacing distance is in a range ofbetween 0.06 inch and 0.08 inch. In some embodiments, the spacingdistance is in a range of between 0.02 inch and 0.06 inch. In someembodiments, the spacing distance is in a range of between 0.04 inch and0.08 inch. In some embodiments, the spacing distance is in a range ofbetween 0.06 inch and 0.12 inch. In some embodiments, the spacingdistance is in a range of between 0.06 inch and 0.08 inch. In someembodiments, the spacing distance is in a range of between 0.08 inch and0.10 inch. In some embodiments, the spacing distance is in a range ofbetween 0.10 inch and 0.12 inch. In some embodiments, the spacingdistance is in a range of between 0.06 inch and 0.10 inch. In someembodiments, the spacing distance is in a range of between 0.08 inch and0.12 inch.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that includes a series ofsimilar individual indicia elements (e.g., lines, curves, letters,symbols, etc.) that are spaced apart from one another along thecorresponding one of the surfaces 112, 114 of the indicator body 102 andare embossed from the corresponding one of the surfaces 112, 114 to anembossing height that varies among the indicia elements (e.g., each ofthe indicia elements has a height that is different from the heights ofsome or all of the remaining ones within the series of the indiciaelements). In some embodiments, the varying embossing heights withinsuch a series of indicia elements are selected so as to enable a user torecognize such indicia elements as indicia elements that are similar toone another but of varying size. In some embodiments, the indiciaelements in the series have varying heights that are in a range ofbetween 0.005 inch and 0.08 inch. In some embodiments, the indiciaelements in the series have varying heights that are in a range ofbetween 0.5 mm and 1.5 mm. In some embodiments, the indicia elements inthe series have varying heights that are in a range of between 3 mm and6 mm. In some embodiments, such a series of indicia elements includesindicia elements having heights of 6 mm, 5.1 mm, 4 mm, and 3.15 mm.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that includes an indiciaelement having a width that varies across a length thereof so as todefine an expanding profile. In some embodiments, the indicia elementhas a width that varies across a range of between 0.05 inch and 0.5inch. In some embodiments, the indicia element has a width that variesacross a range of between 0.05 inch and 0.2 inch. In some embodiments,the indicia element has a width that varies across a range of between0.2 inch and 0.35 inch. In some embodiments, the indicia element has awidth that varies across a range of between 0.35 inch and 0.5 inch. Insome embodiments, the indicia element has a width that varies across arange of between 0.05 inch and 0.35 inch. In some embodiments, theindicia element has a width that varies across a range of between 0.2inch and 0.5 inch.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that includes an embossedportion and a debossed portion. In some embodiments, at least oneindicator 100 within a set of indicators includes a haptic signature 120that includes an embossed portion having an embossing height that is inone of the ranges noted above and a debossed portion. In someembodiments, at least one indicator 100 within a set of indicatorsincludes a haptic signature 120 that includes an embossed portion and adebossed portion having a debossing depth that is one of the rangesnoted above. In some embodiments, at least one indicator 100 within aset of indicators includes a haptic signature 120 that includes anembossed portion that is embossed to a height that is in a range of from1.4 mm to 1.5 mm, or that is in a range of from 1.4 mm to 1.44 mm, orthat is about 1.42 mm, or that is 1.42 mm, and a debossed portion thatis debossed to a depth that is in a range of from 0.8 mm to 1.2 mm, orthat is in a range of from 0.9 mm to 1.1 mm, or that is about 1 mm, orthat is 1 mm. In some embodiments, at least one indicator 100 within aset of indicators includes a haptic signature 120 that includes anembossed portion that is embossed to a height that is in a range of from0.8 mm to 1.2 mm, or that is in a range of from 0.9 mm to 1.1 mm, orthat is about 1 mm, or that is 1 mm, and a debossed portion that isdebossed to a depth that is in a range of from 0.3 mm to 0.7 mm, or thatis in a range of from 0.4 mm to 0.6 mm, or that is about 0.5 mm, or thatis 0.5 mm. In some embodiments, at least one indicator 100 within a setof indicators includes a haptic signature 120 that includes an embossedportion that is embossed to a height that is in a range of from 0.3 mmto 0.7 mm, or that is in a range of from 0.4 mm to 0.6 mm, or that isabout 0.5 mm, or that is 0.5 mm, and a debossed portion that is debossedto a depth that is in a range of from 0.3 mm to 0.7 mm, or that is in arange of from 0.4 mm to 0.6 mm, or that is about 0.5 mm, or that is 0.5mm.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that includes an embossedportion and a debossed/indented portion within the embossed portion. Insome embodiments, at least one indicator 100 within a set of indicatorsincludes a haptic signature 120 that includes an embossed portion havingan embossing height that is in one of the ranges noted above and adebossed/indented portion within the embossed portion. In someembodiments, at least one indicator 100 within a set of indicatorsincludes a haptic signature 120 that includes an embossed portion havingan embossing height that is in one of the ranges noted above and adebossed/indented portion within the embossed portion having a debossingdepth that is one of the ranges noted above. In some embodiments, atleast one indicator 100 within a set of indicators includes a hapticsignature 120 that includes an embossed portion having an embossingheight that is in a range of from 1.7 mm to 2.1 mm, or that is in arange of from 1.8 mm to 2 mm, or that is about 1.9 mm, or that is 1.9mm, and a debossed/indented portion within the embossed portion having adebossing depth that is in a range of from 1.8 mm to 2.2 mm, or that isin a range of from 1.9 mm to 2.1 mm, or that is about 2 mm, or that is 2mm. In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that includes an embossedportion having an embossing height that is in a range of from 1.13 mm to1.53 mm, or that is in a range of from 1.23 mm to 1.43 mm, or that isabout 1.33 mm, or that is 1.33 mm, and a debossed/indented portionwithin the embossed portion having a debossing depth that is in a rangeof from 0.3 mm to 0.7 mm, or that is in a range of from 0.4 mm to 0.6mm, or that is about 0.5 mm, or that is 0.5 mm.

In some embodiments, at least one indicator 100 within a set ofindicators includes a haptic signature 120 that includes a debossedportion and an embossed portion within the debossed portion. In someembodiments, at least one indicator 100 within a set of indicatorsincludes a haptic signature 120 that includes a debossed portion havinga debossing depth that is in one of the ranges noted above and anembossed portion within the debossed portion. In some embodiments, atleast one indicator 100 within a set of indicators includes a hapticsignature 120 that includes a debossed portion having a debossing depththat is in one of the ranges noted above and an embossed portion withinthe debossed portion having an embossing height that is one of theranges noted above. In some embodiments, at least one indicator 100within a set of indicators includes a haptic signature 120 that includesa debossed portion having a debossing depth that is in a range of from0.8 mm to 1.2 mm, or that is in a range of from 0.9 mm to 1.1 mm, orthat is about 1 mm, or that is 1 mm, and an embossed portion within thedebossed portion having an embossing height that is in a range of from0.7 mm to 1.1 mm, or that is in a range of from 0.8 mm to 1 mm, or thatis about 0.9 mm, or that is 0.9 mm.

While not intended to be limiting, several examples of haptic signaturesare listed in Table 1 below, along with information regarding theirspecific applications, metaphors, haptic and visual signatures.

TABLE 1 Haptic signatures Medication Signature/Visual Type and/or andCorresponding Haptic Category Metaphor Haptic Representative Figure GoToMaintenance line; open Raised “GoTo” Lettering as shown in FIGS. line;safe line; logo/lettering. 6 and 15 including a directional arrow; pushline Antihypertensive Control blood pressure Wide higher raised Widesurface lowering to a surface that thin surface resembling graduallychanges graph or on ramp as shown to a thin/low raised in FIG. 24Asurface. Opposite direction of “Pressors.” Downward angle from top leftto bottom right. High and wide surface represents higher blood pressureand the thin/low surface represents a controlled blood pressure. Usertraces wide surface that gradually gets thinner for the finger tofollow. Antibiotics Germs/bacteria Bacteria or germ in Bacteria likeshape that is in a worm shape. the shape of a squiggle line Organicshape and that is overlapping itself. path with a loop User feels a thinsmooth indicating curved line that overlaps, as movement. shown in FIG.25A Arterial Line Blood cell; bright red; Red blood cell. Embossed redblood cell oxygen rich blood Raised circular red (red tag) as shown inFIG. 26A blood cell with indentation in the middle as a metaphor foroxygen rich blood. User feels embossed smooth circular shape withindentation. Venous Line Blood cell; blue; Red blood cell. Debossed redblood cell oxygen poor blood Debossed red (blue tag) as shown in FIG.27A blood cell as a metaphor for oxygen poor blood. Reverse of arterialline. User feels debossed smooth circular shape. Spinal Spinal cordLateral view of Lateral view of spine as Applications spine. Enoughshown in FIG. 28A spacing between the bodies of vertebrae and spinousprocess' for the fingers to distinguish different vertebrae. User feelscolumn of raised surfaces evenly spaced with protruding rounded sectionsout of each surface. Line port cover Incompatible Port cover, DO “Do NotUse” cover as Tag that blocks entry NOT USE shown in FIG. 29 to portIncompatible Must be given alone Triangle with Triangle with exclamationexclamation point point as shown in FIG. 30 indicating to users do notmix/enter/combine. Raised even surface. Antiarrhythmics Wavy, flowy,(EKG Normal heartbeat Normal EKG waves wave) (e.g., common that changesinto transitioning to irregular irregular heart rhythm) an arrhythmia.EKG wave as shown in Thin debossed FIG. 31 wave creates the waves of theEKG. This texture is set to be on a flat surface so that the onlytexture available for the finger to identify is the EKG waves. Half ofthe texture is made to show normal heart rhythm with sharp points/pathsand the second half being an irregular long, wavy, and rounded path.User feels sharp and clean edge/line transitioning to rounded sporadicedge/line Anticoagulant Wave and flow Waving debossed Waves of flowinglines as lines to indicate shown in FIG. 32 standard blood flow. Linesshould have enough separation to distinguish between lines. User feelsseries of lines flowing and waving back and forth running vertically.Narcotics Prickly, agitated, Prickly texture Sporadic spikey texture asloopy/spacey with inconsistent shown in FIG. 33 heights and spacing as ametaphor for being loopy/spacey and confused. Varying heights oftexture. User feels inconsistent prickly texture pressing into finger atdifferent heights, spacing, and sizes. Blood blood, blood drop Blooddrop or Blood drop symbol(s) as Transfusion multiple drops of shown inFIG. 34 blood. Raised smooth surface that starts at a point and roundsout at the bottom. Pressors Squeeze/causing a rise Thin lower raisedThin surface rising to wider in blood pressure. surface that surfaceresembling graph or gradually changes offramp as shown in FIG. 35 into awide higher raised surface from bottom left to top right. Thin and lowrepresents low blood pressure and the upwards increase in size andheight represents high blood pressure. User traces thin surface thatgradually gets wider for the finger to follow. Paralytics Rigidity;rigid Raised human Human form with straight figure with rigid linesrunning from head to lines running toe as shown in FIG. 36 through body.The form of the figure is made up of rigid vertical lines at differentlengths to create the shape of the body. Spacing in between verticallines show that the body is rigid throughout with no organic, wavy, orsoft lines present. Rigid lines should have enough spacing between themto distinguish individual lines. User feels different length verticallines that create a figure. Insulin Course, sandpaper-like Sandpaperstyle Small rough and grainy and granular texture made of texture asshown in FIG. 37 small grains to mimic the feel of sugar. Sedation/Letter Z; sleepy; calm Gradually Large Z's gradually getting Sedativedescending “Z's.” smaller as shown in FIG. 38 Multiple letter Z's in avertical alignment. Z's at the top are larger and raised surfaces thatgradually descend in size and in raised height until the Z is no longera raised surface. User feels raised texture that gradually goes tosmooth flat surface blending into the background of the haptic tag.Chemotherapy Hairy/fuzzy, bald, pale Smooth and bald Unsettled bald faceas color/lime green head/face. Front shown in FIG. 39 (nausea) facinghead with a slight frown or unsettled expression. Raised smooth/roundsurface with no hard edges that is completely bald. User feels smoothembossed surface with facial features. TPN Total parenteral Halfembossed Human form that is nutrition, food/amino human figure/halfembossed on the left and acids-building blocks debossed human debossedon the right as of protein/complete figure. Figure is shown in FIG. 40substance split vertically and divided into two sections. The leftsection is embossed while the right is debossed to show full vs. empty.The left showing full of nutrients and the right showing empty with nonutrients. User feels an embossed form next to its mirrored imagedebossed form. Pediatric Dosing Baby/child Baby figure. Debossed raisedsurface Raised surface of shape of a newborn baby as baby laying on itsshown in FIG. 41 back. Smooth raised surface with human features (arms,head, legs) Potassium Letter K⁺ Letter “K⁺” for Embossed letter K⁺ aschemical symbol shown in FIG. 42 for potassium. Raised even surface.Large enough surface that users can feel/draw the “K” with their finger.User feels crisp and hard edges of embossed shape. In some embodiments,only the letter “K” is used and the “plus” symbol is omitted. ObstetricsMother/child Raised surface of Pregnant female figure as Applicationpregnant woman's shown in FIG. 43 head and torso. User feels embossedsmooth surface - organic form with smaller features and large smoothrounded surface

As illustrated in Table 1, the haptic signatures may correspond tovarious classes of medications (e.g., narcotics, anticoagulants,antiarrhythmics and antibiotics), as well as specific types ofapplications or dosing (e.g., obstetrics and spinal applications,pediatric dosing), functions (e.g., “GoTo” maintenance line (which isfurther discussed below) and line port cover) or anatomical designations(e.g., arterial or venous lines). These haptic signatures are configuredto be easily learned, and remembered, by the caregiver, patient andpatient advocate.

In addition to the haptic signatures, each indicator 100 may have aspecific color and/or shape that is associated with the various classesof medications, specific types of applications or dosing, functions oranatomical designations. Each indicator 100 may further include aspecific luminosity (i.e., glowing in the dark) as a further identifyingcharacteristic. The combination of the identifying characteristics ofcolor, shape, luminosity and haptic signature imbue each indicator 100with a unique, multi-sensory characteristic, or communication. Asdiscussed above, the specific combinations of multi-sensorycommunications alert not only the user (but also the patient, family orpatient advocate) to the contents of the intravenous tubing (e.g.,different classes or types of medications or fluids) and enable the userto take appropriate action in connection therewith. By the patient,family, patient advocate being aware of the medication in use, thisprovides another level of checks and balances to minimize or preventsmedication-related errors that can be catastrophic, and even fatal.

In one embodiment, each indicator 100 includes at least three of theaforesaid identifying characteristics. In another embodiment, eachindicator 100 includes at least four of the aforesaid identifyingcharacteristics. In another embodiment, each indicator 100 includes atleast five of the aforesaid identifying characteristics. In addition tothe identifying characteristics discussed above, text (i.e.,alphanumeric indicia) also constitutes one identifying characteristic insome embodiments.

FIGS. 7-22 illustrate a second embodiment of an intravenous tubingindicator 200 according to the present disclosure. The indicator 200includes a body 202 that is formed from two cooperating members 202 aand 202 b. Each of the members 202 a, 202 b has two opposed ends 204 a,206 a and 204 b, 206 b, respectively. When the members 202 a, 202 b aresecured together (see FIGS. 7-15), the respective ends 204 a, 206 a and204 b, 206 b cooperate to form opposed ends 204, 206 of the body 202.

Referring now to FIGS. 16-22, the member 202 a has opposed sides 208 a,210 a that extend between ends 204 a, 206 a, and opposed inner and outersurfaces 211, 212 that extend between ends 204 a, 206 a and are borderedby sides 208 a, 210 a. The end 204 a defines a partial aperture 216 atherein and the end 206 a defines a partial aperture 218 a therein. Theinner surface 211 defines a channel 215 that extends between partialapertures 216 a, 218 a, and is continuous therewith. The member 202 aalso includes one or more slots 217 formed therein, between the innerand outer surfaces 211, 212. In one exemplary embodiment, there arethree slots 217 (see FIGS. 16 and 18). The channel 215 and slots 217 arediscussed below.

With continued reference to FIGS. 16-22, the member 202 b has a somewhatsimilar construction to that of the member 202 a. The member 202 b hasopposed sides 208 b, 210 b that extend between ends 204 b, 206 b, andopposed inner and outer surfaces 213, 214 that extend between ends 204b, 206 b and are bordered by sides 208 b, 210 b. When the members 202 a,202 b are secured together (see FIGS. 7-15), the respective sides 208 a,210 a and 208 b, 210 b cooperate to form opposed sides 208, 210 of thebody 202. The end 204 b defines a partial aperture 216 b therein and theend 206 b defines a partial aperture 218 b therein. The inner surface213 defines a channel 219 that extends between partial apertures 216 b,218 b, and is continuous therewith. The inner surface 213 also includesone or more tabs 221 extending therefrom. In one exemplary embodiment,there are three tabs 221 (see FIGS. 16 and 18). The channel 219 and tabs221 are discussed below.

Members 202 a and 202 b are connected to each other by one or morehinges 222, which extend between the side 210 a and 210 b. In oneexemplary embodiment, there are three hinges 222 (see FIGS. 17, 18, 21and 22). The hinges 222 enable the indicator body 202 to be moved froman open to a closed position, in which members 202 a and 202 b fullyoverlap and engage one another (see FIGS. 7-15). When the body 202 is inits closed position, partial apertures 216 a, 216 b cooperate to form anaperture 216 at end 204, and partial apertures 218 a, 218 b cooperate toform an aperture 218 at end 206. The channels 215, 219 also cooperatewhen the body 202 is in its closed position to form a bore (not shown).The bore and apertures 216, 218 are dimensioned to receive a length ofintravenous tubing T therethrough. More particularly, and as shown inFIGS. 14 and 15, the intravenous tubing T is inserted through aperture216, extended through the bore within the interior of the indicator body202, and exits therefrom through aperture 118 (not shown). Members 202 aand 202 b are secured to each other via insertion of the tabs 221through their respective slots 217, to maintain the body 202 in itsclosed position. In some embodiments, the channels 215, 219 are sizedand shaped so as to clasp the intravenous tubing T and prevent theintravenous tubing indicator 200 from sliding along the intravenoustubing T.

At least one of the outer surfaces 212, 214 of members 202 a, 202 bincludes a haptic signature 220. The haptic signature 220 is similar tothat of the haptic signature 120 in the first embodiment, in that it mayinclude images, designs, numbers, letters, punctuation marks, patterns,other indicia, or any combination thereof, and is formulated to conveythe nature of the medication or other substance that is contained withinthe intravenous tubing T and being delivered to the patient thereby. Thehaptic signature 220 is formed on the outer surface(s) 212 and/or 214 byany means known in the art, as discussed in connection with theindicator 100 above. The indicator 200 may have the same or similarhaptic signatures as those set out in Table 1 above.

FIG. 23 illustrates another embodiment of the intravenous tubingindicator 200, wherein the interior fastening elements (i.e., slots 217′and tabs 221′) can be of any suitable size and shape.

FIGS. 24A and 24B illustrate another embodiment of the intravenoustubing indicator 300A, which includes opposed peripheral portions 302A,304A, a central portion 306A including a haptic signature 308A for anantihypertensive on a front surface 310A thereof, and a plurality oftabs 312A extending from the central portion 306A (as discussed above)between the opposed peripheral portions 302A, 304A. In some embodiments,the tabs 312A are numbered. In an embodiment, the tabs 312A aresequentially numbered pull or twist-off tabs to indicate the number ofIV bags a patient has used during a period of time. The peripheralportion 302A includes a front surface 314A with identifying indicia316A. FIG. 24B illustrates the rear surface 318A, in which a channel320A is formed. The channel 320A is dimensioned to securely receive anIV line/tube therein. In some embodiments, the channel 320 is sized andshaped so as to prevent the intravenous tubing indicator 300A fromsliding along an IV line/tube that has been received therein. In someembodiments, the intravenous tubing indicator 300 a includes a clasp orother similar retention mechanism positioned and configured so as tofacilitate retention of an IV line/tube in the channel 320A.

FIGS. 25A and 25B illustrate another embodiment of the intravenoustubing indicator 300B, which includes the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a B), except for a haptic signature 308B and identifyingindicia 316B for an antibiotic.

FIGS. 26A and 26B illustrate another embodiment of the vascular tubingindicator 300C, which includes the same structural features as theintravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a C), except for a haptic signature 308C and identifyingindicia 316C for an arterial line.

FIGS. 27A and 27B illustrate another embodiment of the tubing indicator300D, which includes the same structural features as the intravenoustubing indicator 300A of FIGS. 24A and 24B (designated herein with a D),except for a haptic signature 308D and identifying indicia 316D for avenous line.

FIGS. 28A and 28B illustrate another embodiment of the intravenoustubing indicator 300E, which includes the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with an E), except for a haptic signature 308E and identifyingindicia 316E for spinal administration (which may also be referred to as“intrathecal administration”).

FIGS. 29-43 illustrate further embodiments of the intravenous tubingindicator, as discussed below. While not illustrated herein, it is to beunderstood that the rear surfaces of such embodiments are generally thesame as those shown in FIGS. 24B, 25B, 26B, 27B and 28B, including achannel that is dimensioned to securely receive an IV line/tube therein.

FIG. 29 illustrates another embodiment of the tubing indicator 300F(e.g., for arterial, venous, or spinal lines), which includes most ofthe same structural features as the intravenous tubing indicator 300A ofFIGS. 24A and 24B (designated herein with an F), except for a port coverhaptic signature 308F and Do Not Use identifying indicia 316F. In anembodiment, the tubing indicator 300F also lacks tabs. In someembodiments, the intravenous tubing indicator 300F includes anattachment portion that is sized and shaped to attach to and cover aport that is used to administer medication into an intravenous,arterial, or spinal line, thereby preventing medication from beingadministered into the intravenous, arterial, or spinal line.

FIG. 30 illustrates another embodiment of the intravenous tubingindicator 300G, which includes most of the same structural features asthe tubing indicator 300A of FIGS. 24A and 24B (designated herein with aG), except for an incompatible haptic signature 308G and identifyingindicia 316G.

FIG. 31 illustrates another embodiment of the intravenous tubingindicator 300H, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a H), except for an antiarrhythmic haptic signature 308H andidentifying indicia 316H.

FIG. 32 illustrates another embodiment of the intravenous tubingindicator 300J, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a G), except for an anticoagulant haptic signature 308J andidentifying indicia 316J.

FIG. 33 illustrates another embodiment of the intravenous tubingindicator 300K, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a K), except for a narcotic haptic signature 308K andidentifying indicia 316K.

FIG. 34 illustrates another embodiment of the intravenous tubingindicator 300L, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with an L), except for a blood transfusion haptic signature 308Land identifying indicia 316L. The intravenous tubing indicator 300L alsoincludes more tabs than other embodiments.

FIG. 35 illustrates another embodiment of the intravenous tubingindicator 300M, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with an M), except for a pressor haptic signature 308M andidentifying indicia 316M.

FIG. 36 illustrates another embodiment of the intravenous tubingindicator 300N, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with an N), except for a paralytic haptic signature 308N andidentifying indicia 316N.

FIG. 37 illustrates another embodiment of the intravenous tubingindicator 300P, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a P), except for an insulin haptic signature 308P andidentifying indicia 316P. The intravenous tubing indicator 300P alsolacks tabs, as discussed above.

FIG. 38 illustrates another embodiment of the intravenous tubingindicator 300Q, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a Q), except for a sedative haptic signature 308Q andidentifying indicia 316Q.

FIG. 39 illustrates another embodiment of the intravenous tubingindicator 300R, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with an R), except for a chemotherapy haptic signature 308R andidentifying indicia 316R.

FIG. 40 illustrates another embodiment of the intravenous tubingindicator 300S, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a S), except for a TPN haptic signature 308S and identifyingindicia 316S.

FIG. 41 illustrates another embodiment of the intravenous tubingindicator 300T, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a T), except for a pediatric dosing haptic signature 308Tand identifying indicia 316T.

FIG. 42 illustrates another embodiment of the intravenous tubingindicator 300V, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a VP), except for a K⁺ haptic signature 308P and potassiumidentifying indicia 316V.

FIG. 43 illustrates another embodiment of the intravenous tubingindicator 300W, which includes most of the same structural features asthe intravenous tubing indicator 300A of FIGS. 24A and 24B (designatedherein with a W), except for an obstetric haptic signature 308W andidentifying indicia 316W.

In some embodiments, any of the intravenous tubing indicators 300A-300Wshown in FIGS. 23-43 may include images, designs, numbers, letters,punctuation marks, patterns, other indicia, or any combination thereof,and is formulated to convey the nature of the medication or othersubstance that is contained within intravenous tubing to which therespective one of the intravenous tubing indicators 300A-300W isattached and being delivered to the patient thereby. In someembodiments, an image is oriented vertically along one of theintravenous tubing indicators 300A-300W (e.g., oriented generally alonga long axis defined between, for example, the opposed peripheralportions 302A-302W and 304A-304W). In some embodiments, an image isoriented diagonally (e.g., offset from such a long axis).

In some embodiments, an intravenous tubing indicator includes one ormore elongate elements that are positioned along the length of anintravenous tube. In some embodiments, such elongate elements arefabricated by extrusion. In some embodiments, an intravenous tubingindicator configured to be affixed to an intravenous tube includes oneor more discrete elongate elements, and the size, shape, and positioningof the one or more elements will vary depending on the medicament towhich the intravenous tubing indicator corresponds. FIG. 45 illustratesembodiments of such an intravenous tubing indicator. A first intravenoustubing indicator 4510 includes an elongate element 4512 that extendsalong an intravenous tube in a spiral/helical orientation. A secondintravenous tubing indicator 4520 includes a plurality of elongateelements 4522 that extend along an intravenous tube. In someembodiments, each of the elongate elements 4522 extends substantiallylongitudinally along the intravenous tube. In some embodiments, theelongate elements 4522 are divided into groups of the elongate elements4522 that are aligned longitudinally along the intravenous tube andspaced apart circumferentially around the intravenous tube. In someembodiments, the groups of the elongate elements 4522 are spaced apartlongitudinally along the intravenous tube. A third intravenous tubingindicator 4530 includes a plurality of elongate elements 4532 thatextend along an intravenous tube. In some embodiments, each of theelongate elements 4532 extends longitudinally along the intravenoustube. In some embodiments, adjacent ones of the elongate elements 4532are offset from one another both longitudinally along the intravenoustube and circumferentially around the perimeter of the intravenous tube,such that the elongate elements 4532 provide a helical arrangementaround and along the intravenous tube. In some embodiments, theintravenous tubing indicators 4510, 4520, 4530 are color-coded toindicate the contents of the intravenous tubes to which they are joined.In some embodiments, the intravenous tubing indicators 4510, 4520, 4530are used in connection with text labels to indicate the contents of theintravenous tubes to which they are joined.

In some embodiments, an intravenous tubing indicator includes a threadedsheath that extends along an intravenous tube. FIG. 46 illustrateembodiments 4610, 4620, 4630 of such an intravenous tubing indicator. Insome embodiments, the each of the intravenous tubing indicators 4610,4620, 4630 travels back and forth from one side of a correspondingintravenous tube to another in a “zigzag” shape. In some embodiments,the specific shape of each of the intravenous tubing indicators (e.g.,spacing between each repetition, contour at each side of the intravenoustube, etc.) varies from one of the intravenous tubing indicators 4610,4620, 4630 to another. In some embodiments, the intravenous tubingindicators 4610, 4620, 4630 are color-coded to indicate the contents ofthe intravenous tubes to which they are joined. In some embodiments, theintravenous tubing indicators 4610, 4620, 4630 include text labels toindicate the contents of the intravenous tubes to which they are joined.

Referring again to FIGS. 6 and 15, these illustrate embodiments of a“go-to line”, which is the line where emergency medication is injected.The go-to line (depicted in the figures and represented herein as the“GōTo Line”) must have an access port for the administration ofemergency medication and it must satisfy all the requirements for thesafe administration of any emergency medication.

The disclosed system employs identification tags (i.e., indicators 100and 200) that are distributed along the GōTo Line to clearly designatethe line which will always be available for the safe and secureadministration of emergency IV medication.

Sometimes multiple doses of medication are injected or infused during anemergency at different times during a crisis. On many occasions afterstabilizing the patient, the crisis recurs sometime later, at which timethe GoTo line and other haptic indicators will still be immediatelyrecognizable, making the line available for use. For example, multiplesof a single type of medicament-specific haptic indicator (e.g., theindicator 300A of FIGS. 24A and 24B, the indicator 300B of FIGS. 25A and25B, etc.) may remain present on a single intravenous line, indicatingthat such intravenous line is available for further administration ofthe same medicament. In some embodiments, in which such hapticindicators include twist-off tabs to indicate the number of IV bags of amedicament that have been administered to a patient, each of themultiples may have a differently numbered twist-off tab removedtherefrom.

When there is an emergency, such as sudden deterioration in thepatient's condition, it is necessary to find the GōTo Line quickly andconfidently. In some embodiments, a tag identifying the GōTo line ispurposefully and substantially different in appearance from other lineidentification tags to facilitate rapid identification.

In one embodiment, the GōTo Line is identical to a generic infusion lineexcept that it has three special identification tags (e.g., threeinstances of the indicator 100 or of the indicator 200). The tags,affixed at strategic locations along the tube, accomplish routinecritical awareness of the dual role of the line: to identify andfacilitate the prompt location of the line in an emergency.

In one embodiment, the locations of the tags are: (1) near theattachment spike or connector to the bag of fluid; (2) near theperistaltic pump insert or the flow rate adjusting roller clamp, and (3)near the access port at the distal end of tube, closest to theneedle/catheter connection to the patient.

In one embodiment, the locations of the tags also indicate the directionof fluid flow. In one embodiment, the tags include an embossed arrowindicating the direction of fluid flow.

In another embodiment, the tags are attached to the line such that: (1)the tags will not move along the plastic tube; (2) the tags will notinterfere with the use of the line to deliver fluids at specified rateand to keep the vein open; (3) the tags will not interfere with anyother function involving patient care, and (4) the tags are visible.

In some embodiments, each of the tags provides multisensory inputs(e.g., tactile inputs and visual inputs), including multiple types ofvisual inputs (e.g., color, legible text, recognizable image, etc.), toa clinician. In some embodiments, such multisensory inputs enableenhanced and quickened recognition of a tag, and corresponding enhancedand quickened recognition of the content of a given intravenous line, ascompared to prior techniques such as labels written on medical tape. Forexample, in some embodiments, a tag including a tactile input providesenhanced recognition in low-light situations or situations where a labelis positioned in a location that is difficult to view.

In another embodiment, exemplary tags are packaged in a kit including atleast two of the exemplary tags. In some embodiments, a kit includes atleast one tag corresponding to each of at least two differentmedicaments (e.g., at least one of the tag 300A shown in FIGS. 24A and24B, at least one of the tag 300B shown in FIGS. 25A and 25B, at leastone of the tag 300C shown in FIGS. 26A and 26B, etc.). In someembodiments, a kit includes at least one GōTo Line tag such as the tag200 shown in FIGS. 14-23. In some embodiments, a kit includes at leastone port cover tag such as the tag 300F shown in FIG. 29. In someembodiments a kit includes tags as described above, along withinstructions for installation and use of such tags in accordance withthe exemplary embodiments described herein. In some embodiments, a kitincludes at least one tag corresponding to each of a set of differentmedicaments that are the most common medicaments deliveredintravenously. In some embodiments, a kit includes three tags for eachof at least two different medicaments, wherein the three tags for eachspecific medicament are provided for use (A) near the attachment spikeor connector to the bag of fluid containing the specific medicament; (B)near the peristaltic pump insert or the flow rate adjusting rollerclamp, and (C) near the access port at the distal end of tube, closestto the needle/catheter connection to the patient. In some embodiments, akit includes instructions for use of the at least two exemplary tagsincluded in such a kit.

In some embodiments, a kit includes at least a first tag including ahaptic signature that includes an embossed image and a second tagincluding a haptic signature that includes a debossed image. In someembodiments, a kit includes at least a first tag including a hapticsignature that includes an embossed image and a second tag including ahaptic signature that includes a textured portion. In some embodiments,a kit includes at least a first tag including a haptic signature thatincludes a textured portion and a second tag including a hapticsignature that includes a debossed image. In some embodiments, a kitincludes at least a first tag including a haptic signature that includesan embossed image and a second tag including a haptic signature thatincludes a debossed portion within an embossed image. In someembodiments, a kit includes at least a first tag including a hapticsignature that includes an embossed image and a second tag including ahaptic signature that includes an embossed portion within a debossedimage. In some embodiments, a kit includes at least a first tagincluding a haptic signature that includes a debossed image and a secondtag including a haptic signature that includes a debossed portion withinan embossed image. In some embodiments, a kit includes at least a firsttag including a haptic signature that includes a debossed image and asecond tag including a haptic signature that includes an embossedportion within a debossed image. In some embodiments, a kit includes atleast a first tag including a haptic signature that includes a texturedportion and a second tag including a haptic signature that includes adebossed portion within an embossed image. In some embodiments, a kitincludes at least a first tag including a haptic signature that includesa textured portion and a second tag including a haptic signature thatincludes an embossed portion within a debossed image. In someembodiments, a kit includes at least a first tag including a hapticsignature that includes an embossed image, a second tag including ahaptic signature that includes a debossed image, and a third tagincluding a haptic signature that includes a textured portion.

For the GōTo Line to be safe, it must only carry an acceptable fluid,such as normal saline, lactated Ringers, etc., which will not adverselyaffect administration of emergency medication. For the GōTo Line to beeffective, the flow must be sufficient to keep the vein open. In anembodiment, permanent, clear, unambiguous markings of the GōTo Linekeeps the GōTo Line readily recognizable and thereby suitable and safefor subsequent use; and enables confident and timely location of theGōTo Line when it is required in an emergency.

The proper function of the entire system relies on situation-specificdesign characteristics. In one embodiment, these include (1) highvisibility; (2) distinctive shapes; (3) colors which assist in locatingthe line against drapes, equipment, bedding, etc.; (4) Low lightvisibility (luminescence); (5) text that provides an additionalcorroboration of the medicament in the IV line; (6) texture that hasassociation with the contents of the medicament in the IV line; (7)location of tags on the IV line set (A) near the attachment spike orconnector to the bag of fluid; (B) near the peristaltic pump insert orthe flow rate adjusting roller clamp, and (C) near the access port atthe distal end of tube, closest to the needle/catheter connection to thepatient. In such an embodiment, a system of haptic tags is suitable forblind operation under high-stress use scenarios, with augments such ascolor and labeling providing secondary cues to provide safetyredundancy.

Being able to act expeditiously with accuracy and confidence is helpfulto the medical professional both in crisis situations, as well as duringthe performance of routine daily tasks. In a crisis, quick and accurateaction to administer proper medications to the right location can save apatient's life. During the performance of daily routine tasks, amulti-sensory system that communicates a plurality of confirmatorymessages to the care-giver's brain increases the likelihood thatmistakes will be detected and avoided that could otherwise result fromthe lull of repetitive tasks under seemingly “normal” or routinecircumstances. Multi-sensory input tends to compensate for variations inthe degree of reliance upon any particular sense among care-givingpersonnel. For example, color may elicit a stronger recognition responsein one person than another. If only color is used as a differentiator, aperson not particularly attuned to color may not perform as well overthe course of repetitive activities. However, when color, tag shape,patterns, and textures associated with a particular medication aresimultaneously deployed, that same individual may be much more likely toavoid an error even during the dullest or most tiresome circumstances,especially when other tags provide contrast and contradiction as yetanother confirmation-by-contrast sensory input.

Also, it is believed that receiving a multitude of confirmatory anddistinguishing signals allows the brain to quickly achieve a sense ofconfidence in identification. This alleviates the need to laboriouslyinvestigate, ponder and assess; having achieved a sense of confidencefrom multiple-sensory inputs frees up “bandwidth” to proceed with othertasks without confusion and undue delay. Thus, routine tasks can beaccomplished with speed, efficiency and accuracy, all while increasingthe likelihood of “catching” and avoiding potential errors due tofatigue or monotony.

The exemplary embodiments comprise a multi-sensory feedback system toallow medical professionals to expeditiously assess, distinguish andconfirm the current status of multiple medication inputs for a patient.Thus, the combination of lines and tags can communicate a holisticpicture of current medication status, while the inputs from anindividual line provide quick certainty as to its content.

By deploying the exemplary system throughout a care-giving environmentand/or user group, such as a hospital network, military or veteranmedical service, or nationally if standardized, a uniform system isprovided to train staff to act expeditiously with greater confidence andaccuracy in the administration of intravenous medicaments. As staffbecome familiar with the colors, tag shapes, textures, patterns, andtext used to indicate particular families of medications, their speed ofrecognition and ability to act correctly, promptly, and with confidenceincreases. Thus, the multi-sensory feedback system provides an improvedmethod of managing medication administration safely and accurately.

The particular colors, shapes, patterns and/or textures deployed as IVtags can be selected from a wide range of possibilities. Those disclosedin the figures and described herein are merely illustrative of thepossibilities. Once selected, it is preferred that such tags beuniformly deployed in a given facility to ensure consistency andmaximize the speed and accuracy of recognition. The tags placed alongany individual IV tube ideally employ a particular color, texture,pattern or haptic signature and text that differs from and contrastswith other IV lines in use. Both the affirmative communication achievedby the tags on an individual line, as well as the contrasts communicatedfrom neighboring lines, add redundancy to the sensory communicationsthat inform the healthcare worker of the content and status of thelines. By deploying such a system, and using it as a tool to instructattending healthcare professionals, one can achieve an augmented degreeof safety and reliability compared to traditional labeling systems.

Example

Study Description:

To evaluate the effectiveness of the exemplary embodiments in improvingtime to administration and accuracy of emergent bolus drugadministration, a pilot study was designed using a simulated scenarioreplicating the conditions that typically exist in a medical transportor ICU setting (low lighting, motion, cramped quarters, complex multipleIV access sites, life sustaining infusion regimens).

Methods:

A prospective, randomized crossover study was performed in thesimulation lab at the Centre for Emergency Health Sciences in SpringBranch, Tex. Study participants received a 4-minute video orientation ona tag system in accordance with the exemplary embodiments prior tobeginning the study. The following scenario was then presented: The“patient” (a mannequin instrumented with a triple lumen central venouscatheter, four peripheral IV catheters, a double channel IV pump, anendotracheal tube, a chest tube, a nasogastric tube to suction, and aFoley catheter) requires a STAT dose of IV midazolam to treat statusepilepticus. The appropriate line to administer midazolam containsnormal saline and is labeled using (in the case of the control) astandard, tape labeled IV-line or (in the case of the experiment) a tagin accordance with the exemplary embodiments. A photograph of theexperimental tag in accordance with the exemplary embodiments is shownas FIG. 44. The experimental tag in accordance with the exemplaryembodiments included a haptic signature that is embossed at an embossingheight of 0.015 inch. The time to administration was measured by twoindependent observers from the time the participant entered thesimulator to when the midazolam syringe content was pushed into theinfusion line.

Each participant served as their own control by performing thesimulation twice, in random order: once with the tape labeled IV lineand once with tag in accordance with the exemplary embodiments. Thesimulator environment was appropriately noisy, with low lighting and aconfined work space, as may be experienced in an ICU or during medicaltransport. To minimize learning, the appropriate infusion line wasrotated systematically between the four IV sites, and ten (10) minutesseparated the two simulations. Each encounter was videotaped, and anexit questionnaire captured participants' subjective impressions of thetag in accordance with the exemplary embodiments.

Subjects were dichotomized by arm and descriptive statistics were usedto compare demographics between groups. Student T-tests were used tocompare mean time to medication delivery, and differences betweennurses, paramedics and physicians. Order bias (i.e., based on whetherthe tag in accordance with the exemplary embodiments was first or secondin sequence) was also assessed using T-tests.

Results:

For all subjects combined, the mean (+/−SD) time to administration ofmidazolam labeled with a tag in accordance with the exemplaryembodiments (22.79±14.04 seconds) was significantly faster than the mean(+/−SD) time to administration of midazolam labeled with tape as acontrol (37.08±14.49 seconds; p=0.0001). Among paramedics and nurses,administration time was significantly faster statistically, whereas forphysicians there was a faster administration (as indicated in Table 2below with p>0.05). The difference was not attributable to whether thesubject received the tag in accordance with the exemplary embodimentsduring the first or second simulation. One participant chose theincorrect line during their control/tape labeled simulation (i.e., amedication error). In the exit survey, the participants overwhelminglyconcluded that the tag in accordance with the exemplary embodimentsimproved confidence and ease in identifying the appropriate line andthat its use will improve patient safety.

TABLE 2 Exemplary Exemplary GoTo Tag faster # Tag Practitioner TagControl P practitioners % faster (n) (sec) (sec) Value (%) (sec) MD (4)26.8 (11.9) 35.5 (16.5) 0.17 3 (75%) 14.6% Medic (10) 23.9 (14.3) 38.4(10.6) <0.05 9 (90%) 37.3% Nurse (10) 20.1 (15.4) 36.4 (18.1) <0.05 9(90%) 44.7% Total (24) 22.8 (14.0) 37.1 (14.5) <0.05 21 (88%)  36.6%

CONCLUSION

The pilot study results suggest the tag in accordance with the exemplaryembodiments allows STAT drug administration to occur on average 36.6%faster than the tape labeled line.

As will be understood by those familiar with the art, the invention maybe embodied in other specific forms without departing from the spirit oressential characteristics thereof. Likewise, the particular naming anddivision of the modules, features, attributes, methodologies, managersand other aspects are not mandatory or significant, and the mechanismsthat implement the invention or its features may have different names,divisions and/or formats.

It should be emphasized that the above-described embodiments of thepresent disclosure are merely possible examples of implementations thatare set forth for a clear understanding of the principles of thedisclosure. Many variations and modifications may be made to theabove-described embodiment(s) without departing substantially from thespirit and principles of the disclosure. It can be appreciated thatseveral of the above-disclosed and other features and functions, oralternatives thereof, may be desirably combined into many otherdifferent systems or applications. All such modifications and variationsare intended to be included herein within the scope of this disclosure.

What is claimed is:
 1. A system to expedite user recognition ofintravenous line contents, comprising: a plurality of indicator tags,each of which includes a body having a first end, a second end oppositethe first end, a first surface extending from the first end to thesecond end, a second surface opposite the first surface and extendingfrom the first end to the second end, and an aperture extending from thefirst end to the second end and intermediate the first surface and thesecond surface, the aperture being sized and shaped to receive acorresponding intravenous tube, and at least one of the first and secondsurfaces including a haptic signature integrally formed with the atleast one of the first and second surfaces, wherein the plurality ofindicator tags includes at least one tag of a first type and at leastone tag of a second type, wherein the haptic signature of the at leastone tag of the first type includes a first haptic and visual symbol,wherein the first haptic and visual symbol corresponds to first contentsof one of the corresponding intravenous tube, and wherein the hapticsignature of the at least one tag of the second type includes a secondhaptic and visual symbol different in size and shape from the firsthaptic visual symbol, wherein the second haptic and visual symbolcorresponds to second contents of another of the correspondingintravenous tube, wherein the at least one tag of the first type and theat least one tag of the second type is selected from the groupconsisting of: an antihypertensive medication indicator tag, wherein thehaptic signature of the antihypertensive medication indicator tagincludes a first end, a second end opposite the first end of the hapticsignature of the antihypertensive medication indicator tag, a first sidehaving a curvilinear shape and extending from the first end of thehaptic signature of the antihypertensive medication indicator tag to thesecond end of the haptic signature of the antihypertensive medicationindicator tag, a width, and a height, wherein the width graduallydecreases from the first end of the haptic signature of theantihypertensive medication indicator tag to the second end of thehaptic signature of the antihypertensive medication indicator tag, andthe height gradually decreases from the first end of the hapticsignature of the antihypertensive medication indicator tag to the secondend of the haptic signature of the antihypertensive medication indicatortag, an antibiotics medication indicator tag, wherein the hapticsignature of the antibiotics medication indicator tag includes a firstcurved line portion and a second curved line portion overlapping thefirst curved line portion to form a loop, an arterial medicationindicator tag, wherein the haptic signature of the arterial medicationindicator tag includes a circular-shaped embossed portion and acircular-shaped indentation located within the circular-shaped embossedportion, a venous medication indicator tag, wherein the haptic signatureof the venous medication indicator tag includes a circular-shapeddebossed portion and a circular-shaped embossed portion located withinthe circular-shaped debossed portion, a spinal medication indicator tag,wherein the haptic signature of the spinal medication indicator tagincludes a human spine-shape having plurality of vertebrae-shapedportions, an antiarrhythmics medication indicator tag, wherein thehaptic signature of the antiarrhythmics medication indicator tagincludes a wavelength having a first portion with at least onetriangular-shaped wave and a second portion having at least onecurved-shaped wave, an anticoagulant medication indicator tag, whereinthe haptic signature of the anticoagulant medication indicator tagincludes plurality of debossed wavy lines, a narcotics medicationindicator tag, wherein the haptic signature of the narcotics medicationindicator tag includes a plurality of spikes extending from the at leastone of the first and second surfaces and spaced apart from one another,a blood transfusion indicator tag, wherein the haptic signature of theblood transfusion medication indicator tag includes a plurality ofdrop-shaped portions, each of which includes a first pointed end and asecond rounded end that is wider than the first pointed end, a pressormedication indicator tag, wherein the haptic signature of the pressormedication indicator tag includes a first end, a second end opposite thefirst end of the haptic signature of the pressor medication indicatortag, a first side having a curvilinear shape and extending from thefirst end of the haptic signature of the pressor medication indicatortag to the second end of the haptic signature of the pressor medicationindicator tag, a width, and a height, wherein the width of the hapticsignature of the pressor medication indicator tag gradually increasesfrom the first end of the haptic signature of the pressor medicationindicator tag to the second end of the haptic signature of the pressormedication indicator tag, and the height of the haptic signature of thepressor medication indicator tag gradually increases from the first endof the haptic signature of the pressor medication indicator tag to thesecond end of the haptic signature of the pressor medication indicatortag, a paralytics medication indicator tag, wherein the haptic signatureof the paralytics medication indicator tag includes a human-shapedportion having a first end, a second end opposite the first end of thehuman-shaped portion, and at least one channel formed therein andextending from the first end of the human-shaped portion to the secondend of the human-shaped portion, an insulin medication indicator tag,wherein the haptic signature of the insulin medication indicator tagincludes a grainy texture, a sedative medication indicator tag, whereinthe haptic signature of the sedative medication indicator tag includes aplurality of Z-letter shaped portions, wherein the plurality of Z-lettershaped portions is oriented in a column, wherein each of the pluralityof Z-letter shaped portions includes a height, wherein the height ofeach of the Z-letter shaped portions gradually decreases from a firstone of the Z-letter shaped portions to a succeeding one of the Z-lettershaped portions, a chemotherapy medication indicator tag, wherein thehaptic signature of the chemotherapy medication indicator tag includes ahuman head-shaped portion having a rounded first end, a TPN nutritionindicator tag, wherein the haptic signature of the TPN medicationindicator tag includes a human-shaped portion having an embossed portionand debossed portion, a pediatric dosing medication indicator tag,wherein the haptic signature of the pediatric dosing medicationindicator tag includes a human baby-shaped debossed portion, a potassiummedication indicator tag, wherein the haptic signature of the potassiummedication indicator tag includes a K-shaped embossment, an obstetricsmedication indicator tag, wherein the haptic signature of the obstetricsmedication indicator tag includes an embossment having a shape of apregnant woman, and an incompatible indicator tag, wherein the hapticsignature of the incompatible indicator tag includes an embossedtriangle and an embossed exclamation point character within thetriangle.
 2. The system of claim 1, wherein the system includes threeindicator tags of the first type, wherein each of the three indicatortags of the first type is configured to be secured at a differentlocation along its corresponding intravenous tube.
 3. The system ofclaim 2, wherein a first one of the indicator tags of the first type isconfigured to be secured to the corresponding intravenous tube near aconnector to a bag of fluid, a second one of the indicator tags of thefirst type is configured to be secured to the corresponding intravenoustube near a peristaltic pump insert or a flow rate adjusting rollerclamp, and a third one of the indicator tags of the first type isconfigured to be secured to the corresponding intravenous tube near anaccess port at a distal end of the corresponding intravenous tube. 4.The system of claim 1, wherein the plurality of indicator tags includesan additional medicament indicator tag, wherein the haptic signature ofthe additional medicament indicator tag includes an embossed text phraseGoTo.
 5. The system of claim 4, wherein the body of the additionalmedicament indicator tag is green in color.
 6. The system of claim 1,wherein the texture of the insulin medication indicator tad includes aplurality of hemispherical dots having heights in a range of from 0.17mm to 1 mm and a center-to-center spacing between adjacent dots in arange of from 1 mm to 1.5 mm.
 7. The system of claim 1, wherein thetexture of the insulin medication indicator tag includes a plurality ofhemispherical dots having heights in a range of from 1 mm to 1.2 mm anda center-to-center spacing between adjacent dots in a range of that isfrom 1.5 mm to 2.5 mm.
 8. A system to expedite user recognition ofintravenous line contents, comprising: at least two intravenous tubes,each of which has a proximal end, a distal end opposite the proximalend, and a middle portion intermediate the proximal and distal ends,wherein a first one of the intravenous tubes carries first contents andwherein a second one of the intravenous tubes carries second contents; aplurality of indicator tags, each of which includes a surface, each ofthe indicator tags is configured to be attached to one of the at leasttwo intravenous tubes, and wherein each of the indicator tags includes ahaptic signature integrally formed with the surface and providingmulti-sensory input to a user, wherein the plurality of indicator tagsincludes at least a first type of indicator tag having a first color, afirst shape, and a first texture and a second type of indicator taghaving a second color different from the first color, a first shapedifferent from the second shape, and a second texture different from thefirst texture, wherein the haptic signature the first type of indicatortag includes a first haptic and visual symbol, wherein the first color,the first shape, the first texture and the first haptic and visualsymbol provides a first type of multi-sensory input indicative of thefirst contents, wherein a first one of the first type of indicator tagis attached to the first one of the intravenous tubes at the proximalend of the first one of the intravenous tubes, wherein a second one ofthe first type of indicator tag is attached to the first one of theintravenous tubes at the middle portion of the first one of theintravenous tubes, wherein a third one of the first type of indicatortag is attached to the first one of the intravenous tubes at the distalend of the first one of the intravenous tubes, wherein the hapticsignature of the second type of indicator tag includes a second hapticand visual symbol that is different in size and shape from the firsthaptic and visual symbol, wherein the second color, the second shape,the second texture and the second haptic and visual symbol provides asecond type of multi-sensory input different from the first type ofmulti-sensory input and indicative of the second contents, wherein afirst one of the second type of indicator tag is attached to the secondone of the intravenous tubes at the proximal end of the second one ofthe intravenous tubes, wherein a second one of the second type ofindicator tag is attached to the second one of the intravenous tubes atthe middle portion of the second one of the intravenous tubes, wherein athird one of the second type of indicator tag is attached to the secondone of the intravenous tubes at the distal end of the second one of theintravenous tubes, wherein the at least one tag of the first type andthe at least one tag of the second type is selected from the groupconsisting of: an antihypertensive medication indicator tag, wherein thehaptic signature of the antihypertensive medication indicator tagincludes a first end, a second end opposite the first end of the hapticsignature of the antihypertensive medication indicator tag, a first sidehaving a curvilinear shape and extending from the first end of thehaptic signature of the antihypertensive medication indicator tag to thesecond end of the haptic signature of the antihypertensive medicationindicator tag, a width, and a height, wherein the width graduallydecreases from the first end of the haptic signature of theantihypertensive medication indicator tag to the second end of thehaptic signature of the antihypertensive medication indicator tag, andthe height gradually decreases from the first end of the hapticsignature of the antihypertensive medication indicator tag to the secondend of the haptic signature of the antihypertensive medication indicatortag, an antibiotics medication indicator tag, wherein the hapticsignature of the antibiotics medication indicator tag includes a firstcurved line portion and a second curved line portion overlapping thefirst curved line portion to form a loop, an arterial medicationindicator tag, wherein the haptic signature of the arterial medicationindicator tag includes a circular-shaped embossed portion and acircular-shaped indentation located within the circular-shaped embossedportion, a venous medication indicator tag, wherein the haptic signatureof the venous medication indicator tag includes a circular-shapeddebossed portion and a circular-shaped embossed portion located withinthe circular-shaped debossed portion, a spinal medication indicator tag,wherein the haptic signature of the spinal medication indicator tagincludes a human spine-shape having plurality of vertebrae-shapedportions, an antiarrhythmics medication indicator tag, wherein thehaptic signature of the antiarrhythmics medication indicator tagincludes a wavelength having a first portion with at least onetriangular-shaped wave and a second portion having at least onecurved-shaped wave, an anticoagulant medication indicator tag, whereinthe haptic signature of the anticoagulant medication indicator tagincludes plurality of debossed wavy lines, a narcotics medicationindicator tag, wherein the haptic signature of the narcotics medicationindicator tag includes a plurality of spikes extending from the at leastone of the first and second surfaces and spaced apart from one another,a blood transfusion indicator tag, wherein the haptic signature of theblood transfusion medication indicator tag includes a plurality ofdrop-shaped portions, each of which includes a first pointed end and asecond rounded end that is wider than the first pointed end, a pressormedication indicator tag, wherein the haptic signature of the pressormedication indicator tag includes a first end, a second end opposite thefirst end of the haptic signature of the pressor medication indicatortag, a first side having a curvilinear shape and extending from thefirst end of the haptic signature of the pressor medication indicatortag to the second end of the haptic signature of the pressor medicationindicator tag, a width, and a height, wherein the width of the hapticsignature of the pressor medication indicator tag gradually increasesfrom the first end of the haptic signature of the pressor medicationindicator tag to the second end of the haptic signature of the pressormedication indicator tag, and the height of the haptic signature of thepressor medication indicator tag gradually increases from the first endof the haptic signature of the pressor medication indicator tag to thesecond end of the haptic signature of the pressor medication indicatortag, a paralytics medication indicator tag, wherein the haptic signatureof the paralytics medication indicator tag includes a human-shapedportion having a first end, a second end opposite the first end of thehuman-shaped portion, and at least one channel formed therein andextending from the first end of the human-shaped portion to the secondend of the human-shaped portion, an insulin medication indicator tag,wherein the haptic signature of the insulin medication indicator tagincludes a grainy texture, a sedative medication indicator tag, whereinthe haptic signature of the sedative medication indicator tag includes aplurality of Z-letter shaped portions, wherein the plurality of Z-lettershaped portions is oriented in a column, wherein each of the pluralityof Z-letter shaped portions includes a height, wherein the height ofeach of the Z-letter shaped portions gradually decreases from a firstone of the Z-letter shaped portions to a succeeding one of the Z-lettershaped portions, a chemotherapy medication indicator tag, wherein thehaptic signature of the chemotherapy medication indicator tag includes ahuman head-shaped portion having a rounded first end, a TPN nutritionindicator tag, wherein the haptic signature of the TPN medicationindicator tag includes a human-shaped portion having an embossed portionand debossed portion, a pediatric dosing medication indicator tag,wherein the haptic signature of the pediatric dosing medicationindicator tag includes a human baby-shaped debossed portion, a potassiummedication indicator tag, wherein the haptic signature of the potassiummedication indicator tag includes a K-shaped embossment, an obstetricsmedication indicator tag, wherein the haptic signature of the obstetricsmedication indicator tag includes an embossment having a shape of apregnant woman, and an incompatible indicator tag, wherein the hapticsignature of the incompatible indicator tag includes an embossedtriangle and an embossed exclamation point character within thetriangle.
 9. The system of claim 8, wherein the group of the pluralityof indicator tags includes an additional medicament indicator tag,wherein the haptic signature of the additional medicament indicator tagincludes an embossed text phrase GoTo, wherein text phrase is configuredto identify to a user that the corresponding intravenous tube isavailable for administration of at least one additional medicament. 10.The system of claim 9, wherein the body of the additional medicamentindicator tag is green in color.
 11. A kit, comprising: a plurality ofindicator tags, each of which includes a body having a first end, asecond end opposite the first end, a first surface extending from thefirst end to the second end, and a haptic signature integrally formedwith the first surface, wherein each of the indicator tags is configuredto be attached to an intravenous tube, and wherein the plurality ofindicator tags includes an antihypertensive medication indicator tag,wherein the haptic signature of the antihypertensive medicationindicator tag includes a first end, a second end opposite the first endof the haptic signature of the antihypertensive medication indicatortag, a first side having a curvilinear shape and extending from thefirst end of the haptic signature of the antihypertensive medicationindicator tag to the second end of the haptic signature of theantihypertensive medication indicator tag, a width, and a height,wherein the width gradually decreases from the first end of the hapticsignature of the antihypertensive medication indicator tag to the secondend of the haptic signature of the antihypertensive medication indicatortag, and the height gradually decreases from the first end of the hapticsignature of the antihypertensive medication indicator tag to the secondend of the haptic signature of the antihypertensive medication indicatortag, an antibiotics medication indicator tag, wherein the hapticsignature of the antibiotics medication indicator tag includes a firstcurved line portion and a second curved line portion overlapping thefirst curved line portion to form a loop, an arterial medicationindicator tag, wherein the haptic signature of the arterial medicationindicator tag includes a circular-shaped embossed portion and acircular-shaped indentation located within the circular-shaped embossedportion, a venous medication indicator tag, wherein the haptic signatureof the venous medication indicator tag includes a circular-shapeddebossed portion and a circular-shaped embossed portion located withinthe circular-shaped debossed portion, a spinal medication indicator tag,wherein the haptic signature of the spinal medication indicator tagincludes a human spine-shape having plurality of vertebrae-shapedportions, an antiarrhythmics medication indicator tag, wherein thehaptic signature of the antiarrhythmics medication indicator tagincludes a wavelength having a first portion with at least onetriangular-shaped wave and a second portion having at least onecurved-shaped wave, an anticoagulant medication indicator tag, whereinthe haptic signature of the anticoagulant medication indicator tagincludes plurality of debossed wavy lines, a narcotics medicationindicator tag, wherein the haptic signature of the narcotics medicationindicator tag includes a plurality of spikes extending from the at leastone of the first and second surfaces and spaced apart from one another,a blood transfusion indicator tag, wherein the haptic signature of theblood transfusion medication indicator tag includes a plurality ofdrop-shaped portions, each of which includes a first pointed end and asecond rounded end that is wider than the first pointed end, a pressormedication indicator tag, wherein the haptic signature of the pressormedication indicator tag includes a first end, a second end opposite thefirst end of the haptic signature of the pressor medication indicatortag, a first side having a curvilinear shape and extending from thefirst end of the haptic signature of the pressor medication indicatortag to the second end of the haptic signature of the pressor medicationindicator tag, a width, and a height, wherein the width of the hapticsignature of the pressor medication indicator tag gradually increasesfrom the first end of the haptic signature of the pressor medicationindicator tag to the second end of the haptic signature of the pressormedication indicator tag, and the height of the haptic signature of thepressor medication indicator tag gradually increases from the first endof the haptic signature of the pressor medication indicator tag to thesecond end of the haptic signature of the pressor medication indicatortag, a paralytics medication indicator tag, wherein the haptic signatureof the paralytics medication indicator tag includes a human-shapedportion having a first end, a second end opposite the first end of thehuman-shaped portion, and at least one channel formed therein andextending from the first end of the human-shaped portion to the secondend of the human-shaped portion, an insulin medication indicator tag,wherein the haptic signature of the insulin medication indicator tagincludes a grainy texture, a sedative medication indicator tag, whereinthe haptic signature of the sedative medication indicator tag includes aplurality of Z-letter shaped portions, wherein the plurality of Z-lettershaped portions is oriented in a column, wherein each of the pluralityof Z-letter shaped portions includes a height, wherein the height ofeach of the Z-letter shaped portions gradually decreases from a firstone of the Z-letter shaped portions to a succeeding one of the Z-lettershaped portions, a chemotherapy medication indicator tag, wherein thehaptic signature of the chemotherapy medication indicator tag includes ahuman head-shaped portion having a rounded first end, a TPN nutritionindicator tag, wherein the haptic signature of the TPN medicationindicator tag includes a human-shaped portion having an embossed portionand debossed portion, a pediatric dosing medication indicator tag,wherein the haptic signature of the pediatric dosing medicationindicator tag includes a human baby-shaped debossed portion, a potassiummedication indicator tag, wherein the haptic signature of the potassiummedication indicator tag includes a K-shaped embossment, an obstetricsmedication indicator tag, wherein the haptic signature of the obstetricsmedication indicator tag includes an embossment having a shape of apregnant woman, and an incompatible indicator tag, wherein the hapticsignature of the incompatible indicator tag includes an embossedtriangle and an embossed exclamation point character within thetriangle.
 12. The kit of claim 11, wherein the plurality of indicatortags includes an additional medicament indicator tag, wherein the hapticsignature of the additional medicament indicator tag includes anembossed text phrase GoTo.
 13. The kit of claim 12, wherein the body ofthe additional medicament indicator tag is green in color.